Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit

Primary or acquired resistant mechanisms prevent the employment of individualized therapy with target drugs like the mTOR inhibitor everolimus (EVE) in hepatocellular carcinoma (HCC). The current study evaluated the effect of 1,25(OH)(2)Vitamin D (VitD) treatment on EVE sensitivity in established mo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Autores principales: Provvisiero, Donatella Paola, Negri, Mariarosaria, de Angelis, Cristina, Di Gennaro, Gilda, Patalano, Roberta, Simeoli, Chiara, Papa, Fortuna, Ferrigno, Rosario, Auriemma, Renata Simona, De Martino, Maria Cristina, Colao, Annamaria, Pivonello, Rosario, Pivonello, Claudia
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6690984/
https://ncbi.nlm.nih.gov/pubmed/31406139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-48081-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares